A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN)
European Urology Focus · 2024
DOI: 10.1016/j.euf.2023.09.017 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Urology Focus, 2024. Verfasst von Jon Rees und 9 weiteren Autor:innen. Beteiligte Einrichtung: Brockway Medical Centre, Tyntesfield Medical Group, Bristol, UK. Hauptthemen laut MEDLINE: Muscarinic Antagonists, Urinary Bladder, Overactive, Databases, Factual. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Patients with overactive bladder may cycle through different antimuscarinic medications even though there is limited evidence to support this approach. OBJECTIVE: To describe treatment patterns and the associated health care resource utilisation (HCRU) according to antimuscarinic cycling groups. DESIGN, SETTING, AND PARTICIPANTS: The CYCLe AntiMuscarinics in ENgland (CYCLAMEN) study was a retrospective observational investigation that used primary care records from the Clinical Practice Research Datalink GOLD database linked to Hospital Episode Statistics secondary care data. Eligible patients (≥18 yr) were prescribed their first antimuscarinic between January 2014 and December 2017. Patients were categorised into groups prescribed one, two, or three or more (groups 1-3) consecutive unique antimuscarinics over 18 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The HCRU rate and costs were calculated for the period of continuous antimuscarinic therapy (first antimuscarinic treatment episode) and the 18-mo follow-up period. Treatment sequence patterns were displayed using sunburst plots and Kaplan-Meier analysis was used to assess time on treatment. RESULTS AND LIMITATIONS: Overall, 35 369 patients were included, of whom 31 760 (89.8%) received one antimuscarinic (group 1), 3182 (9.0%) received two (group 2), and 427 (1.2%) received three or more (group 3). The most common initial antimuscarinics were solifenacin (13 628 patients, 42.9%) in group 1, and oxybutynin in group 2 (1267 patients, 39.8%) and group 3 (200 patients, 46.8%). The median duration of the first antimuscarinic treatment episode was 57 d and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brockway Medical Centre, Tyntesfield Medical Group, Bristol, UK.
- Astellas Pharma Europe Ltd., Addlestone, UK.
- Astellas Pharma Europe Ltd., Addlestone, UK. Electronic address: mahmood_ali@astellas.com.
- Data Science, Astellas Pharma B.V., Leiden, The Netherlands.
- Astellas Pharma Ltd., Woking, UK.
- Royal Hallamshire Hospital, Sheffield, UK.
Zitieren
APA
Rees, J., Martins de Almeida, R., Ali, M., Covernton, P. J. O., Stoelzel, M., Leyland, K. M., Irwin, L., Scrine, L., Hansen, M. K., & Chapple, C. (2024). A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN). European Urology Focus. https://doi.org/10.1016/j.euf.2023.09.017
Vancouver
Rees J, Martins de Almeida R, Ali M, Covernton PJO, Stoelzel M, Leyland KM, et al. A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN). European Urology Focus. 2024. doi:10.1016/j.euf.2023.09.017
BibTeX
@article{Rees2024,
author = {Rees, Jon and Martins de Almeida, Rodrigo and Ali, Mahmood and Covernton, Patrick J O and Stoelzel, Matthias and Leyland, Kirsten M and Irwin, Lucy and Scrine, Ludmila and Hansen, Merete Kock and Chapple, Christopher},
title = {A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN)},
journal = {European Urology Focus},
year = {2024},
doi = {10.1016/j.euf.2023.09.017}
}
EUVIMED